18d
Sagimet Biosciences Highlights Denifanstat MASH Data, Combo Plans at Oppenheimer Healthcare Conf.
Sagimet Biosciences (NASDAQ:SGMT) used an investor discussion at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference to outline its strategy around fatty acid synthase (FASN) inhibition, ...
Completed Phase 1 pharmacokinetic (PK) clinical trial of denifanstat and resmetirom combination Phase 2 trial of ...
Oppenheimer 36th Annual Healthcare Life Sciences Conference February 26, 2026 9:20 AM ESTCompany ParticipantsDavid Happel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results